Showing 51–75 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Dinesh Kumar Sharma
…ad to the successful creation of a novel class of potent TB vaccines. This article addresses tuberculosis infection diagnosis, pathophysiology, immunology, and advanced nanoparticles to deliver TB vaccines and anti-TB drugs. The challenges and prospects for the future in creating…
Jan T Poolman
…n. Advances in bacteriology and immunology signify that Mtb vaccines need to induce responses from multiple components of the immune system, over and above Th1 responses targeted by most current vaccine candidates. This review provides an update on key features of Mtb bacteriolog…
Jason R Andrews, Salome Charalambous, Gavin Churchyard, Frank Cobelens, Carlos Fernández-Escobar, et al.
… ultimately, elimination. Currently, there are over a dozen vaccines in clinical development, although none of the ongoing or planned trials include people deprived of liberty. Several factors contribute to this exclusion, including historical ethical violations in medical resear…
Ayman Elbehiry, Eman Marzouk, Husam M Edrees, Riyad AlShaqi, Abousree T Ellethy, et al.
…the Xpert MTB/RIF Ultra, BPaLM regimen, and next-generation vaccines such as M72/AS01E represent pivotal progress, their deployment remains uneven. Implementation science, cost-effectiveness analyses, and health equity considerations are vital to scaling up these tools. Moreover,…
Qianfei Liu, Songnian Que, Yixuan Qiu, Mingxing Tang, Shaohua Liu, et al.
…toinfection is a key aspect of the development of effective vaccines and immunotherapies to eradicate tuberculosis. In this review, we delve into the overview of animal models of TB infection and the host's innate and adaptive immune responses toinfection. We discuss howis recogn…
Shuying Zhang, Juan Cheng, Yuanyuan Tang
…efforts should be focused on the development of multivalent vaccines, the integration of chemoimmunotherapy, and the sharing of global monitoring data to contribute to the ultimate goal of eliminating tuberculosis.
Thales A Campelo, Natália S Oliveira, Pedro F N Souza, Denis F G de-Oliveira, Cristiane C Frota, et al.
The Bacillus Calmette-Guérin (BCG) vaccine, used against tuberculosis for a century, shows promise in protecting against viral infections through trained/innate immunity. This review maps clinical and preclinical studies on both parental (WT) and recombinant BCG (rBCG) again…
Emma Lefrançais, Denis Hudrisier, Olivier Neyrolles, Samuel M Behar, Joel D Ernst
…n insights that can inform the design of T cell-targeted TB vaccines.
Pankti C. Balar, Bedanta Bhattacharjee, Dixa A. Vaghela, Lalitkumar K. Vora, Vasso Apostolopoulos, et al.
…ntrol, with a specific focus on the pivotal roles played by vaccines and biomarkers. This chapter includes the latest advancements in TB vaccine research, highlighting novel candidates and approaches that show promise in providing more effective protection against Mycobacterium t…
Alex Odoom, Abdul-Halim Osman, Christian K O Dzuvor
…peutic agents, including monoclonal antibodies, therapeutic vaccines, cellular therapies, and immunomodulators, have been developed and explored to treat drug-resistant bacterial infections. This review comprehensively summarizes recent advancements in immunotherapies and vaccine…
Matthew Milton, Salah Mansour
…mising pathway for universally protective tuberculosis (TB) vaccines. This review explores the biology of CD1 isoforms, the functional diversity of CD1-restricted T cell subsets, and their roles in TB immunity. We discuss Mtb's lipid antigens, mechanisms of CD1 trafficking and an…
Taehwan Oh
Spatial transcriptomics (ST) enables genome-wide gene expression profiling while preserving tissue architecture, bridging the gap between bulk, single-cell, and histological analyses. Originating in 2016 and rapidly evolving since, ST has transformed infectious disease research b…
Magdalena Druszczynska, Beata Sadowska, Jakub Kulesza, Ewelina Kulesza, Marek Fol
The Bacillus Calmette-Guérin (BCG) vaccine, originally developed for tuberculosis (TB) prevention, has recently attracted attention due to its broader immunomodulatory properties. In addition to its role in TB control, BCG induces trained immunity, a process involving epigen…
Gamze Tanriver, Salman Ali Khan, Artur Góra, Novel N Chegou, Shima Mahmoudi
Tuberculosis (TB) remains a significant global health challenge, necessitating continued research efforts to unravel its complex pathogenesis and advance diagnostic, therapeutic, and preventive strategies. Resuscitation-promoting factors (Rpfs) are peptidoglycan-hydrolyzing enzym…
Cesar Augusto Roque-Borda, Subham Kumar Vishwakarma, Oswaldo Julio Ramirez Delgado, Heitor Leocadio de Souza Rodrigues, Laura M D Primo, et al.
… to host-directed defense. Second, we discuss peptide-based vaccines designed to elicit robust and durable protective immunity, representing a complementary alternative to classical vaccine approaches. Third, we highlight the synergistic potential of AMPs in combination with firs…
Nurudeen Oketade, Melissa D Chengalroyen, Dylan Kain, David M Lewinsohn, Karen M Dobos
Flavin and deazaflavin biosynthesis are highly conserved pathways in mycobacteria, including in(Flavin biosynthesis on one hand is required to produce FMN and FAD, two essential cofactors required to support the flavin intensive lifestyle of mycobacteria. Deazaflavin biosynthesis…
Joshua D Bromley, Andrew W Simonson, Alex K Shalek, JoAnne L Flynn
Tuberculosis (TB) disease states and outcomes are highly heterogeneous. While this makes TB difficult to diagnose, monitor, and treat, it also presents opportunities to identify correlates of protection or disease severity that can be used as biomarkers and help inform future int…
Samantha Vermaak, Samantha L. Sampson, Helen McShane
Abstract Established in June 2017, VALIDATE is an international network of researchers working to accelerate vaccine development for four neglected intracellular pathogens that cause significant mortality and morbidity globally: Mycobacterium tuberculosis , Leishmania spp., Burkh…
Tim J. Bull
…history, development and efficacy of the different types of vaccines against <italic>Mycobacterium avium</italic> subsp. <italic>paratuberculosis</italic>.
Leontine Nkague Nkamba, Thomas Timothee Manga
This paper focuses on the study and control of a non linear mathematical epidemic model (S Svih V E LI ) based on a system of ordinary differential equation modeling the spread of tuberculosis infectious with VIH/AIDS coinfection. Existence of both disease free equilibrium and en…
Jesús Gonzalo‐Asensio, Nacho Aguiló, Dessislava Marinova, Carlos Martı́n
Tuberculosis (TB) is the biggest killer of humanity. TB has killed more human beings than any other infectious disease in history, with an estimated loss of over a billion lives in the past 200 years (1). Despite effective treatment, in the WHO 2016 there were an estimated 10.4 m…
Hazel Morrison, Helen McShane
…gainst tuberculosis (TB). It is one of the most widely used vaccines in the world, having been administered to over four billion people, with another 100 million children vaccinated with BCG every year. Despite this, significant debate exists surrounding its efficacy against TB a…
Cara Adolph, Simon C Mendelsohn, Laura E Via, Leonardo Martinez, Cecilia S Lindestam Arlehamn, et al.
Tuberculosis remains a leading cause of death, underscoring the urgent need for a new vaccine. Progress in vaccine development is hampered by incomplete understanding of how Mycobacterium tuberculosis causes infection and disease, and of protective immunity following natural infe…
Rasmus Mortensen, Cecilia S Lindestam Arlehamn, Rhea N Coler, Michael Y Gerner, Delia Goletti, et al.
Tuberculosis (TB) remains a leading infectious cause of morbidity and mortality, and the development of a new, highly effective vaccine would have a tremendous beneficial impact on global health. Although conventional memory CD4 and CD8 T cells will likely be key mediators of lon…
Aidé Tamara Staines-Boone, Edna Venegas-Montoya, Jorge Alberto García Campos, Jennifer Alejandra Obregón García, Julieta C Marmolejo Bjirsdorp, et al.
… with known or suspected immune deficiencies and delay live vaccines until 6 months of age.